Jazz Pharmaceuticals | Sustainability Performance
Jazz Pharmaceuticals develops and markets pharmaceutical products, with a focus on treating rare and complex conditions. Its portfolio includes therapies for sleep disorders, oncology, and neurology.
2003
Ireland
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
N/A in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#10202
Overallⓘ#67
in Irelandⓘ#241
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsSocial
Diversity and InclusionFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Controversy level
- Jazz Pharmaceuticals' Xyrem pricing faced scrutiny for creating financial access barriers for narcolepsy patients.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.